NDA 017871 · Bausch
Demser
Metyrosine · Oral · Catecholamine Synthesis Inhibitor
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jul 15, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1979
Oct 3, 1979
Approved uses
1
Original approval plus efficacy supplements
Registered trials
13
1 Phase 3, 0 recruiting
FAERS reports
81
69 serious, 21 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 1, 2021.
INDICATIONS AND USAGE DEMSER is indicated in the treatment of patients with pheochromocytoma for: 1. Preoperative preparation of patients for surgery 2. Management of patients when surgery is contraindicated 3. Chronic treatment of patients with malignant pheochromocytoma DEMSER is not recommended for the control of essential hypertension.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 3, 1979 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- DEMSER · METYROSINE 250MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Metyrosine" as an intervention, any sponsor and status, largest first.
- A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic CancerPivotal-lookingTerminated
Tyme, IncIndustry
NCT03512756 · 130 participants · Start Mar 27, 2018 · Primary completion Dec 28, 2021
Drug: SM-88 used with MPS (methoxsalen, phenytoin, sirolimus); Capecitabine, Gemcitabine, and 5-FU · For: Pancreatic Cancer
Sites: Birmingham, Alabama; Duarte, California; Santa Monica, California · 20 sites in all
University of BernAcademic, hospital or other
NCT02179814 · 60 participants (planned) · Start Feb 20, 2012 · Primary completion May 2019
Drug: AMPT/ Demser; Diphenhydramine and 1 more · For: Bulimia Nervosa; Eating Disorders; Dopamine and 2 more
Sites: Bern, Switzerland
Yamo Pharmaceuticals LLCIndustry
NCT05067582 · 58 participants · Start Jan 25, 2022 · Primary completion Jun 18, 2024
Drug: L1-79 · For: Autism Spectrum Disorder; Autism
Sites: Phoenix, Arizona; Orange, California; San Rafael, California · 8 sites in all
National Institute of Mental Health (NIMH)NIH
NCT00062946 · 45 participants · Start Jun 17, 2003
Drug: (18F)fallypride · For: Healthy
Sites: Bethesda, Maryland
Yamo Pharmaceuticals LLCIndustry
NCT02947048 · 42 participants · Start Oct 2016 · Primary completion Dec 2017
Drug: L1-79; Placebo · For: Autism
Sites: Livingston, New Jersey; Sea Girt, New Jersey
Mansoura University HospitalAcademic, hospital or other
NCT04482959 · 40 participants · Start Jul 15, 2020 · Primary completion Dec 30, 2021
Drug: Carbetocin; Sodium chloride 0.9% · For: Myoma;Uterus
Sites: Al Mansurah, Egypt
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00028106 · 32 participants · Start Dec 5, 2001
Drug: [131]I-MIBG; 6-[18F]Fluorodopamine and 1 more · For: Pheochromocytoma
Sites: Bethesda, Maryland
- SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for SarcomaActive, not recruiting
Sarcoma Oncology Research Center, LLCAcademic, hospital or other
NCT03778996 · 31 participants · Start Jan 3, 2020 · Primary completion Dec 19, 2027
Drug: Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS) · For: Sarcoma, Ewing; Sarcoma
Sites: Santa Monica, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use16
- somnolence12
- pneumonia7
- diarrhoea6
- pyrexia6
- drug ineffective5
- hospitalisation5
- malaise5
- phaeochromocytoma4
- vomiting4
- blood pressure increased3
- constipation3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 4 |
| 2017 | 6 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 5 |
| 2021 | 9 |
| 2022 | 6 |
| 2023 | 13 |
| 2024 | 4 |
| 2025 | 16 |
| 2026 | 6 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Demser (Metyrosine)
2024 spending
$233K
Beneficiaries
n/a
13 claims
Per beneficiary
n/a
$406.92 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,068,803 |
| 2021 | $1,090,580 |
| 2022 | $225,809 |
| 2023 | $320,548 |
| 2024 | $233,163 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of L1-79 on Core Symptoms of Autism Spectrum Disorder: A Case Series.
Rothman J, Bartky EJ, Halas FP · Clin Ther 2019 · Clinical Trial, Multicenter Study
- Efficacy and safety of metyrosine in pheochromocytoma/paraganglioma: a multi-center trial in Japan.
Naruse M, Satoh F, Tanabe A, et al. · Endocr J 2018 · Clinical Trial, Phase I, Clinical Trial, Phase II
- The Role for Metyrosine in the Treatment of Patients With Pheochromocytoma and Paraganglioma.
Gruber LM, Jasim S, Ducharme-Smith A, et al. · J Clin Endocrinol Metab 2021 · Research Support, N.I.H., Extramural, Systematic Review
- Surgical management of pheochromocytoma with the use of metyrosine.
Perry RR, Keiser HR, Norton JA, et al. · Ann Surg 1990 · Clinical Trial, Controlled Clinical Trial
- Catecholamine depletion produces irrepressible saccadic eye movements in normal humans.
Tychsen L, Sitaram N · Ann Neurol 1989 · Clinical Trial, Controlled Clinical Trial
- Neuroleptic-potentiating effect of metyrosine.
Magelund G, Gerlach J, Casey DE · Am J Psychiatry 1979 · Clinical Trial, Comparative Study
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.